Anti-angiogenic properties of artemisinin derivatives (Review)

Wei,Tianshu; Liu,Ju

doi:10.3892/ijmm.2017.3085

Anti-angiogenic properties of artemisinin derivatives (Review)

Authors:
- Tianshu Wei
- Ju Liu
View Affiliations

Affiliations: School of Population and Global Health, The University of Melbourne, Victoria 3010, Australia, Laboratory of Microvascular Medicine, Medical Research Center, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong 250014, P.R. China
Published online on: July 31, 2017 https://doi.org/10.3892/ijmm.2017.3085
Pages: 972-978

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Angiogenesis, the process involving the development of new blood vessels from existing capillaries, is critical for growth and wound healing. However, pathological angiogenesis contributes to the pathogeneses of numerous diseases, including cancer, rheumatoid arthritis, diabetic retinopathy and macular degeneration. Hence, the inhibition of angiogenesis is an effective therapeutic approach for these diseases. Apart from its anti-malarial properties, artemisinin and its derivatives also exhibit potent anti-angiogenic properties. The molecular mechanisms underlying their inhibitory effects on angiogenesis have been studied by several groups. These investigations have revealed that artemisinins inhibit angiogenesis via the perturbations of cellular signaling pathways involved in the regulation of angiogenesis. Along with a brief introduction to artemisinin derivatives, this review provides a detailed summary of the effects of artemisinins on the mitogen-activated protein kinase (MAPK) pathway, the nuclear factor-κB (NF-κB) pathway and the phosphatidylinositide 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) pathway. Due to the multiplicity of their actions on relevant signaling pathways, artemisinins are promising candidates with potential for use as anti-angiogenic agents for the treatment of related diseases or disorders.

View Figures

View References

1	Dong F, Tian H, Yan S, Li L, Dong X, Wang F, Li J, Li C, Cao Z, Liu X, et al: Dihydroartemisinin inhibits endothelial cell proliferation through the suppression of the ERK signaling pathway. Int J Mol Med. 35:1381–1387. 2015. View Article : Google Scholar : PubMed/NCBI
2	Dong F, Zhou X, Li C, Yan S, Deng X, Cao Z, Li L, Tang B, Allen TD and Liu J: Dihydroartemisinin targets VEGFR2 via the NF-κB pathway in endothelial cells to inhibit angiogenesis. Cancer Biol Ther. 15:1479–1488. 2014. View Article : Google Scholar
3	Guo L, Dong F, Hou Y, Cai W, Zhou X, Huang AL, Yang M, Allen TD and Liu J: Dihydroartemisinin inhibits vascular endothelial growth factor-induced endothelial cell migration by a p38 mitogen-activated protein kinase-independent pathway. Exp Ther Med. 8:1707–1712. 2014. View Article : Google Scholar : PubMed/NCBI
4	Oh S, Jeong IH, Shin WS and Lee S: Growth inhibition activity of thioacetal artemisinin derivatives against human umbilical vein endothelial cells. Bioorg Med Chem Lett. 13:3665–3668. 2003. View Article : Google Scholar : PubMed/NCBI
5	Oh S, Jeong IH, Ahn CM, Shin WS and Lee S: Synthesis and antiangiogenic activity of thioacetal artemisinin derivatives. Bioorg Med Chem. 12:3783–3790. 2004. View Article : Google Scholar : PubMed/NCBI
6	Oh S, Jeong IH, Shin WS and Lee S: Synthesis and antiangiogenic activity of exo-olefinated deoxoartemisinin derivatives. Bioorg Med Chem Lett. 14:3683–3686. 2004. View Article : Google Scholar : PubMed/NCBI
7	Ricci J, Park J, Chung WY, Park KK and Jung M: Concise synthesis and antiangiogenic activity of artemisinin-glycolipid hybrids on chorioallantoic membranes. Bioorg Med Chem Lett. 20:6858–6860. 2010. View Article : Google Scholar : PubMed/NCBI
8	Risau W: Mechanisms of angiogenesis. Nature. 386:671–674. 1997. View Article : Google Scholar : PubMed/NCBI
9	Ho WE, Peh HY, Chan TK and Wong WS: Artemisinins: Pharmacological actions beyond anti-malarial. Pharmacol Ther. 142:126–139. 2014. View Article : Google Scholar
10	Carmeliet P and Jain RK: Molecular mechanisms and clinical applications of angiogenesis. Nature. 473:298–307. 2011. View Article : Google Scholar : PubMed/NCBI
11	Cheng R, Li C, Li C, Wei L, Li L, Zhang Y, Yao Y, Gu X, Cai W, Yang Z, et al: The artemisinin derivative artesunate inhibits corneal neovascularization by inducing ROS-dependent apoptosis in vascular endothelial cells. Invest Ophthalmol Vis Sci. 54:3400–3409. 2013. View Article : Google Scholar : PubMed/NCBI
12	Nagy JA, Dvorak AM and Dvorak HF: VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol. 2:251–275. 2007. View Article : Google Scholar : PubMed/NCBI
13	Ferrara N: VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2:795–803. 2002. View Article : Google Scholar : PubMed/NCBI
14	Ferrara N: VEGF-A: A critical regulator of blood vessel growth. Eur Cytokine Netw. 20:158–163. 2009.
15	Crespo-Ortiz MP and Wei MQ: Antitumor activity of artemisinin and its derivatives: From a well-known antimalarial agent to a potential anticancer drug. J Biomed Biotechnol. 2012:2475972012. View Article : Google Scholar
16	Arden GB, Wolf JE and Tsang Y: Does dark adaptation exacerbate diabetic retinopathy? Evidence and a linking hypothesis. Vision Res. 38:1723–1729. 1998. View Article : Google Scholar : PubMed/NCBI
17	Crawford TN, Alfaro DV III, Kerrison JB and Jablon EP: Diabetic retinopathy and angiogenesis. Curr Diabetes Rev. 5:8–13. 2009. View Article : Google Scholar : PubMed/NCBI
18	He Y, Fan J, Lin H, Yang X, Ye Y, Liang L, Zhan Z, Dong X, Sun L and Xu H: The anti-malaria agent artesunate inhibits expression of vascular endothelial growth factor and hypoxia-inducible factor-1α in human rheumatoid arthritis fibroblast-like synoviocyte. Rheumatol Int. 31:53–60. 2011. View Article : Google Scholar
19	Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1:27–31. 1995. View Article : Google Scholar : PubMed/NCBI
20	Polverini PJ: Angiogenesis in health and disease: Insights into basic mechanisms and therapeutic opportunities. J Dent Educ. 66:962–975. 2002.PubMed/NCBI
21	Wang SJ, Sun B, Cheng ZX, Zhou HX, Gao Y, Kong R, Chen H, Jiang HC, Pan SH, Xue DB, et al: Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF-κB pathway. Cancer Chemother Pharmacol. 68:1421–1430. 2011. View Article : Google Scholar : PubMed/NCBI
22	Jeong E, Song HJ, Lim S, Lee SJ, Lim JE, Nam DH, Joo KM, Jeong BC, Jeon SS, Choi HY, et al: Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis. Oncotarget. 6:33046–33064. 2015. View Article : Google Scholar : PubMed/NCBI
23	Zhu XX, Yang L, Li YJ, Zhang D, Chen Y, Kostecká P, Kmoníčková E and Zídek Z: Effects of sesquiterpene, flavonoid and coumarin types of compounds from Artemisia annua L. on production of mediators of angiogenesis. Pharmacol Rep. 65:410–420. 2013. View Article : Google Scholar : PubMed/NCBI
24	Odaka Y, Xu B, Luo Y, Shen T, Shang C, Wu Y, Zhou H and Huang S: Dihydroartemisinin inhibits the mammalian target of rapamycin-mediated signaling pathways in tumor cells. Carcinogenesis. 35:192–200. 2014. View Article : Google Scholar
25	Hay N and Sonenberg N: Upstream and downstream of mTOR. Genes Dev. 18:1926–1945. 2004. View Article : Google Scholar : PubMed/NCBI
26	Corsello MA and Garg NK: Synthetic chemistry fuels interdisciplinary approaches to the production of artemisinin. Nat Prod Rep. 32:359–366. 2015. View Article : Google Scholar
27	Mott BT, He R, Chen X, Fox JM, Civin CI, Arav-Boger R and Posner GH: Artemisinin-derived dimer phosphate esters as potent anti-cytomegalovirus (anti-CMV) and anticancer agents: A structure-activity study. Bioorg Med Chem. 21:3702–3707. 2013. View Article : Google Scholar : PubMed/NCBI
28	Lee S: Artemisinin, promising lead natural product for various drug developments. Mini Rev Med Chem. 7:411–422. 2007. View Article : Google Scholar : PubMed/NCBI
29	Singh NP and Panwar VK: Case report of a pituitary macroadenoma treated with artemether. Integr Cancer Ther. 5:391–394. 2006. View Article : Google Scholar : PubMed/NCBI
30	Chen H, Shi L, Yang X, Li S, Guo X and Pan L: Artesunate inhibiting angiogenesis induced by human myeloma RPMI-8226 cells. Int J Hematol. 92:587–597. 2010. View Article : Google Scholar : PubMed/NCBI
31	Nagelschmitz J, Voith B, Wensing G, Roemer A, Fugmann B, Haynes RK, Kotecka BM, Rieckmann KH and Edstein MD: First assessment in humans of the safety, tolerability, pharmacokinetics, and ex vivo pharmacodynamic antimalarial activity of the new artemisinin derivative artemisone. Antimicrob Agents Chemother. 52:3085–3091. 2008. View Article : Google Scholar : PubMed/NCBI
32	Ansari MT, Saify ZS, Sultana N, Ahmad I, Saeed-Ul-Hassan S, Tariq I and Khanum M: Malaria and artemisinin derivatives: An updated review. Mini Rev Med Chem. 13:1879–1902. 2013. View Article : Google Scholar : PubMed/NCBI
33	Haynes RK, Fugmann B, Stetter J, Rieckmann K, Heilmann HD, Chan HW, Cheung MK, Lam WL, Wong HN, Croft SL, et al: Artemisone - a highly active antimalarial drug of the artemisinin class. Angew Chem Int Ed Engl. 45:2082–2088. 2006. View Article : Google Scholar : PubMed/NCBI
34	Jung M, Tak J, Chung WY and Park KK: Antiangiogenic activity of deoxoartemisinin derivatives on chorioallantoic membrane. Bioorg Med Chem Lett. 16:1227–1230. 2006. View Article : Google Scholar
35	Shen K, Ji L, Lu B and Wang Z: c-Jun N-terminal kinase mediated VEGFR2 sustained phosphorylation is critical for VEGFA-induced angiogenesis in vitro and in vivo. Cell Biochem Biophys. 64:17–27. 2012. View Article : Google Scholar : PubMed/NCBI
36	Miura S, Matsuo Y and Saku K: Jun N-terminal kinase inhibitor blocks angiogenesis by blocking VEGF secretion and an MMP pathway. J Atheroscler Thromb. 15:69–74. 2008. View Article : Google Scholar : PubMed/NCBI
37	Grossi V, Peserico A, Tezil T and Simone C: p38α MAPK pathway: A key factor in colorectal cancer therapy and chemoresistance. World J Gastroenterol. 20:9744–9758. 2014. View Article : Google Scholar : PubMed/NCBI
38	Li Z, Meng D, Li G, Xu J, Tian K and Li Y: Celecoxib combined with diacerein effectively alleviates osteoarthritis in rats via regulating JNK and p38MAPK signaling pathways. Inflammation. 38:1563–1572. 2015. View Article : Google Scholar : PubMed/NCBI
39	Ma X, Liu Y, Wang Q, Chen Y, Liu M, Li X, Xiang R, Wei Y, Duan Y and Han J: Tamoxifen induces the development of hernia in mice by activating MMP-2 and MMP-13 expression. Biochim Biophys Acta. 1852:1038–1048. 2015. View Article : Google Scholar : PubMed/NCBI
40	Sato Y, Kanno S, Oda N, Abe M, Ito M, Shitara K and Shibuya M: Properties of two VEGF receptors, Flt-1 and KDR, in signal transduction. Ann NY Acad Sci. 902:201–207. 2000. View Article : Google Scholar : PubMed/NCBI
41	Szade A, Grochot-Przeczek A, Florczyk U, Jozkowicz A and Dulak J: Cellular and molecular mechanisms of inflammation-induced angiogenesis. IUBMB Life. 67:145–159. 2015. View Article : Google Scholar : PubMed/NCBI
42	Gupta K, Kshirsagar S, Li W, Gui L, Ramakrishnan S, Gupta P, Law PY and Hebbel RP: VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp Cell Res. 247:495–504. 1999. View Article : Google Scholar : PubMed/NCBI
43	Weston CR and Davis RJ: The JNK signal transduction pathway. Curr Opin Cell Biol. 19:142–149. 2007. View Article : Google Scholar : PubMed/NCBI
44	Dong F, Han J, Jing G, Chen X, Yan S, Yue L, Cao Z, Liu X, Ma G and Liu J: Dihydroartemisinin transiently activates the JNK/SAPK signaling pathway in endothelial cells. Oncol Lett. 12:4699–4704. 2016.
45	Firestone GL and Sundar S: Anticancer activities of artemisinin and its bioactive derivatives. Expert Rev Mol Med. 11:e322009. View Article : Google Scholar : PubMed/NCBI
46	Devasagayam TP, Tilak JC, Boloor KK, Sane KS, Ghaskadbi SS and Lele RD: Free radicals and antioxidants in human health: Current status and future prospects. J Assoc Physicians India. 52:794–804. 2004.
47	Hayden MS and Ghosh S: Shared principles in NF-kappaB signaling. Cell. 132:344–362. 2008. View Article : Google Scholar : PubMed/NCBI
48	Oliver KM, Taylor CT and Cummins EP: Hypoxia. Regulation of NFkappaB signalling during inflammation: The role of hydroxylases. Arthritis Res Ther. 11:2152009. View Article : Google Scholar : PubMed/NCBI
49	Hsiao KY, Chang N, Lin SC, Li YH and Wu MH: Inhibition of dual specificity phosphatase-2 by hypoxia promotes interleukin-8-mediated angiogenesis in endometriosis. Hum Reprod. 29:2747–2755. 2014. View Article : Google Scholar : PubMed/NCBI
50	Suffee N, Richard B, Hlawaty H, Oudar O, Charnaux N and Sutton A: Angiogenic properties of the chemokine RANTES/CCL5. Biochem Soc Trans. 39:1649–1653. 2011. View Article : Google Scholar : PubMed/NCBI
51	Mateo J, García-Lecea M, Cadenas S, Hernández C and Moncada S: Regulation of hypoxia-inducible factor-1alpha by nitric oxide through mitochondria-dependent and -independent pathways. Biochem J. 376:537–544. 2003. View Article : Google Scholar : PubMed/NCBI
52	Xu H, He Y, Yang X, Liang L, Zhan Z, Ye Y, Yang X, Lian F and Sun L: Anti-malarial agent artesunate inhibits TNF-alpha-induced production of proinflammatory cytokines via inhibition of NF-kappaB and PI3 kinase/Akt signal pathway in human rheumatoid arthritis fibroblast-like synoviocytes. Rheumatology (Oxford). 46:920–926. 2007. View Article : Google Scholar
53	Karar J and Maity A: PI3K/AKT/mTOR pathway in angiogenesis. Front Mol Neurosci. 4:512011. View Article : Google Scholar : PubMed/NCBI
54	Masoud GN and Li W: HIF-1α pathway: Role, regulation and intervention for cancer therapy. Acta Pharm Sin B. 5:378–389. 2015. View Article : Google Scholar : PubMed/NCBI
55	Zhao YG, Wang Y, Guo Z, Gu AD, Dan HC, Baldwin AS, Hao W and Wan YY: Dihydroartemisinin ameliorates inflammatory disease by its reciprocal effects on Th and regulatory T cell function via modulating the mammalian target of rapamycin pathway. J Immunol. 189:4417–4425. 2012. View Article : Google Scholar : PubMed/NCBI
56	Chen Q, Chen L, Wu X, Zhang F, Jin H, Lu C, Shao J, Kong D, Wu L and Zheng S: Dihydroartemisinin prevents liver fibrosis in bile duct ligated rats by inducing hepatic stellate cell apoptosis through modulating the PI3K/Akt pathway. IUBMB Life. 68:220–231. 2016. View Article : Google Scholar : PubMed/NCBI
57	Feng X, Li L, Jiang H, Jiang K, Jin Y and Zheng J: Dihydroartemisinin potentiates the anticancer effect of cisplatin via mTOR inhibition in cisplatin-resistant ovarian cancer cells: Involvement of apoptosis and autophagy. Biochem Biophys Res Commun. 444:376–381. 2014. View Article : Google Scholar : PubMed/NCBI
58	Liao K, Li J and Wang Z: Dihydroartemisinin inhibits cell proliferation via AKT/GSK3β/cyclinD1 pathway and induces apoptosis in A549 lung cancer cells. Int J Clin Exp Pathol. 7:8684–8691. 2014.
59	Tan SS, Ong B, Cheng C, Ho WE, Tam JK, Stewart AG, Harris T, Wong WS and Tran T: The antimalarial drug artesunate inhibits primary human cultured airway smooth muscle cell proliferation. Am J Respir Cell Mol Biol. 50:451–458. 2014.